Cargando…
Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin
BACKGROUND: We evaluated possible diagnostic and prognostic values of serum midkine in malignant pleural mesothelioma in comparison with those of serum mesothelin, a well-established diagnostic biomarker. METHODS: Serum mesothelin and midkine levels were determined with an enzyme-linked immunosorben...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362983/ https://www.ncbi.nlm.nih.gov/pubmed/28335760 http://dx.doi.org/10.1186/s12885-017-3209-5 |
_version_ | 1782517083695742976 |
---|---|
author | Ak, Guntulu Tada, Yuji Shimada, Hideaki Metintas, Selma Ito, Masaaki Hiroshima, Kenzo Tagawa, Masatoshi Metintas, Muzaffer |
author_facet | Ak, Guntulu Tada, Yuji Shimada, Hideaki Metintas, Selma Ito, Masaaki Hiroshima, Kenzo Tagawa, Masatoshi Metintas, Muzaffer |
author_sort | Ak, Guntulu |
collection | PubMed |
description | BACKGROUND: We evaluated possible diagnostic and prognostic values of serum midkine in malignant pleural mesothelioma in comparison with those of serum mesothelin, a well-established diagnostic biomarker. METHODS: Serum mesothelin and midkine levels were determined with an enzyme-linked immunosorbent assay. We examined specimens from 95 Turkish cases with malignant pleural mesothelioma, 56 metastatic cancers to pleura, 27 other types of benign pleural diseases and 20 benign asbestos pleurisy. The cut-off values were 1.5 nmol/L for mesothelin and 421 pg/mL for midkine. RESULTS: Sensitivity and specificity of mesothelin were 51.6 and 71.4%, 51.6 and 85.2%, and 51.6 and 85% for differentiating mesothelioma from metastatic cancers to pleura, other benign pleural diseases and benign asbestos pleurisy, respectively. Sensitivity and specificity of midkine were 61.1 and 41.1%, 61.1 and 48.1%, and 61.1 and 75% to distinguish mesothelioma from metastatic cancers to pleura, other benign pleural diseases and benign asbestos pleurisy, respectively. Combination of both biomarkers did not improve the differential diagnostic efficacy. Mesothelin levels were elevated in the epitheloid type and in the advanced cases, but were not related to the prognosis. In contrast, elevated baseline levels of midkine were independently associated with a poor prognosis of mesothelioma patients after adjusting for the stage, the histological subtypes and treatment schedules (HR = 1.84; 95% CI: 1.09-3.09) (p = 0.022). CONCLUSIONS: Serum mesothelin showed moderate sensitivity and high specificity to differentiate malignant pleural mesothelioma from metastatic malignancy to pleura and from benign pleural diseases. In contrast, midkine was a useful marker for predicting prognosis of mesothelioma patients. |
format | Online Article Text |
id | pubmed-5362983 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53629832017-03-24 Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin Ak, Guntulu Tada, Yuji Shimada, Hideaki Metintas, Selma Ito, Masaaki Hiroshima, Kenzo Tagawa, Masatoshi Metintas, Muzaffer BMC Cancer Research Article BACKGROUND: We evaluated possible diagnostic and prognostic values of serum midkine in malignant pleural mesothelioma in comparison with those of serum mesothelin, a well-established diagnostic biomarker. METHODS: Serum mesothelin and midkine levels were determined with an enzyme-linked immunosorbent assay. We examined specimens from 95 Turkish cases with malignant pleural mesothelioma, 56 metastatic cancers to pleura, 27 other types of benign pleural diseases and 20 benign asbestos pleurisy. The cut-off values were 1.5 nmol/L for mesothelin and 421 pg/mL for midkine. RESULTS: Sensitivity and specificity of mesothelin were 51.6 and 71.4%, 51.6 and 85.2%, and 51.6 and 85% for differentiating mesothelioma from metastatic cancers to pleura, other benign pleural diseases and benign asbestos pleurisy, respectively. Sensitivity and specificity of midkine were 61.1 and 41.1%, 61.1 and 48.1%, and 61.1 and 75% to distinguish mesothelioma from metastatic cancers to pleura, other benign pleural diseases and benign asbestos pleurisy, respectively. Combination of both biomarkers did not improve the differential diagnostic efficacy. Mesothelin levels were elevated in the epitheloid type and in the advanced cases, but were not related to the prognosis. In contrast, elevated baseline levels of midkine were independently associated with a poor prognosis of mesothelioma patients after adjusting for the stage, the histological subtypes and treatment schedules (HR = 1.84; 95% CI: 1.09-3.09) (p = 0.022). CONCLUSIONS: Serum mesothelin showed moderate sensitivity and high specificity to differentiate malignant pleural mesothelioma from metastatic malignancy to pleura and from benign pleural diseases. In contrast, midkine was a useful marker for predicting prognosis of mesothelioma patients. BioMed Central 2017-03-23 /pmc/articles/PMC5362983/ /pubmed/28335760 http://dx.doi.org/10.1186/s12885-017-3209-5 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Ak, Guntulu Tada, Yuji Shimada, Hideaki Metintas, Selma Ito, Masaaki Hiroshima, Kenzo Tagawa, Masatoshi Metintas, Muzaffer Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin |
title | Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin |
title_full | Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin |
title_fullStr | Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin |
title_full_unstemmed | Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin |
title_short | Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin |
title_sort | midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362983/ https://www.ncbi.nlm.nih.gov/pubmed/28335760 http://dx.doi.org/10.1186/s12885-017-3209-5 |
work_keys_str_mv | AT akguntulu midkineisapotentialnovelmarkerformalignantmesotheliomawithdifferentprognosticanddiagnosticvaluesfrommesothelin AT tadayuji midkineisapotentialnovelmarkerformalignantmesotheliomawithdifferentprognosticanddiagnosticvaluesfrommesothelin AT shimadahideaki midkineisapotentialnovelmarkerformalignantmesotheliomawithdifferentprognosticanddiagnosticvaluesfrommesothelin AT metintasselma midkineisapotentialnovelmarkerformalignantmesotheliomawithdifferentprognosticanddiagnosticvaluesfrommesothelin AT itomasaaki midkineisapotentialnovelmarkerformalignantmesotheliomawithdifferentprognosticanddiagnosticvaluesfrommesothelin AT hiroshimakenzo midkineisapotentialnovelmarkerformalignantmesotheliomawithdifferentprognosticanddiagnosticvaluesfrommesothelin AT tagawamasatoshi midkineisapotentialnovelmarkerformalignantmesotheliomawithdifferentprognosticanddiagnosticvaluesfrommesothelin AT metintasmuzaffer midkineisapotentialnovelmarkerformalignantmesotheliomawithdifferentprognosticanddiagnosticvaluesfrommesothelin |